BACKGROUND: The tall cell variant (TCV) of papillary thyroid cancer is reported to have a poor prognosis. This study examines the incidence and end result of surgical treatment of TCV. METHODS: In this study, 240 thyroid cancers treated over a 23-year period at two hospital centers are reviewed. A total of 153 patients with papillary cancer were available for follow-up. All microscopic slides were re-examined. RESULTS: Of the total 183 papillary cancers, 19 (10.4%) were TCV. The remainder were usual papillary or other papillary cancer variants. Patient age, tumor size, lymph node and soft-tissue involvement, recurrence, and death rates were evaluated. Multivariate statistical analysis disclosed that TCV histology, as well as age and tumor size, were significant predictors of recurrence. CONCLUSION: Despite a high rate of recurrence in TCV cases over age 50 (6/9), there were no recurrent TCVs in cases under age 50 (0/8). Pathologists and surgeons must develop an increased awareness of this entity and implications for more radical treatment in the older age group.
BACKGROUND: The tall cell variant (TCV) of papillary thyroid cancer is reported to have a poor prognosis. This study examines the incidence and end result of surgical treatment of TCV. METHODS: In this study, 240 thyroid cancers treated over a 23-year period at two hospital centers are reviewed. A total of 153 patients with papillary cancer were available for follow-up. All microscopic slides were re-examined. RESULTS: Of the total 183 papillary cancers, 19 (10.4%) were TCV. The remainder were usual papillary or other papillary cancer variants. Patient age, tumor size, lymph node and soft-tissue involvement, recurrence, and death rates were evaluated. Multivariate statistical analysis disclosed that TCV histology, as well as age and tumor size, were significant predictors of recurrence. CONCLUSION: Despite a high rate of recurrence in TCV cases over age 50 (6/9), there were no recurrent TCVs in cases under age 50 (0/8). Pathologists and surgeons must develop an increased awareness of this entity and implications for more radical treatment in the older age group.
Authors: C Regalbuto; P Malandrino; F Frasca; G Pellegriti; R Le Moli; R Vigneri; V Pezzino Journal: J Endocrinol Invest Date: 2012-07-09 Impact factor: 4.256
Authors: M Russo; P Malandrino; M Moleti; F Vermiglio; M A Violi; I Marturano; E Minaldi; R Vigneri; G Pellegriti; C Regalbuto Journal: J Endocrinol Invest Date: 2017-05-20 Impact factor: 4.256
Authors: Laura Y Wang; Iain J Nixon; Snehal G Patel; Frank L Palmer; R Michael Tuttle; Ashok Shaha; Jatin P Shah; Ian Ganly Journal: Surgery Date: 2016-06-11 Impact factor: 3.982
Authors: Paolo Miccoli; Michele N Minuto; Clara Ugolini; Erica Panicucci; Piero Berti; Marco Massi; Fulvio Basolo Journal: World J Surg Date: 2007-05 Impact factor: 3.352